Randomized, Double-blind, Placebo-controlled Study in Patients With Fistulizing Crohn's Disease

Summary

The primary objective of this study is to investigate the safety and tolerability of locally administered DLX105 in treating enterocutaneous fistulas in Crohn's Disease patients. The study will consist of a screening period of approx. 2 weeks, a 4-week treatment period and a 2-week follow-up period. An end-of study visit is scheduled on Day 43, 2 weeks after the last study visit.

Timeline

Start

2012-06

Primary completion

2013-02

Completion

2013-08

Drugs

Indications